Whippany, NJ (August 28, 2006) - Image Solutions, Inc., (ISI) a global technology company and leader in providing software solutions and services for electronic regulatory submissions and clinical trials management, announced today that they have been awarded their sixth Deloitte & Touche LLP’s New Jersey Technology Fast 50 Award for 2006. The award is given to companies in NJ that demonstrate phenomenal revenue growth during the period 2001-2006, and show strength, vision and temerity to succeed in today’s very competitive technology environment.
Paul Mlynarski, a partner with Deloitte Tax LLP and chairperson of Deloitte’s New Jersey Technology Fast 50 stated that, “Sustaining high revenue growth over five years is an exceptional accomplishment. We commend Image Solutions, Inc. for making the commitment to technology and delivering on the promise of market longevity. We are proud to honor Image Solutions, Inc. and their CEO Jinsoo Kim as a Deloitte Technology Fast 50 winner”.
To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2001 and $5,000,000 in 2005, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify.
Winners of the 16 regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte’s Technology Fast 500 program, which ranks North America’s top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte’s Technology Fast 50 or Technology Fast 500 programs, visit www.fast500.com.
Image Solutions, Inc. is considered a pioneer in developing technology solutions for Pharmaceutical and Biotechnology companies worldwide, and has attributed their sustained revenue growth to increasing demand in this market for electronic document systems that can provide greater efficiency, increase collaboration, speed time-to-market and reduce inefficiencies typically associated with handling and storing paper documents.
ISI’s CFO/ VP of Finance, Peter Kim stated that “We believe our continued revenue growth demonstrates a growing recognition by the worldwide pharmaceutical and biotechnology industry that ISI is a leader, in terms of value-added technology and professional services, that help pharmaceutical sponsors reduce drug development and submission costs and bring products to market quickly.”
When asked about ISI’s future plans, Peter Kim summarized, “All of this activity further improves our already strong balance sheet, and with our 11% reinvestment in R&D again this year, ISI is expected to continue to grow our best-in-class technology approach with our existing products and services, and continue to add new products and services to our portfolio over the next year. ISI is also proud to have continued a tradition of contributing 10% of net profit each year to charitable organizations like the United Way, The Red Cross, Salvation Army, UNICEF and over 20 other charitable organizations.